Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3716 results
DBV Technologies to develop Viaskin Milk for eosinophilic esophagitis treatment
By PBR Staff Writer
France-based DBV Technologies, creator of Viaskin, a new paradigm for the treatment of allergies, has signed a clinical agreement with Dr. Jonathan Spergel at The Children's Hospital of Philadelphia to carry out a clinical trial to develop Viaskin Milk for the treatment of milk-induced eosinophilic esophagitis (EoE) in children.
Drug Research > Drug Discovery & Development > News
Jubilant, Orion enter into drug discovery program in pain management area
By PBR Staff Writer
Jubilant Biosys, Indian subsidiary of Jubilant Life Sciences, and Finish pharmaceutical firm Orion have entered into a drug discovery collaboration to identify small molecule inhibitors in the neuroscience therapeutic area.
Drug Research > Drug Discovery & Development > News
MabVax Therapeutics and Telik sign definitive merger agreement
MabVax Therapeutics, a privately held cancer immunotherapy company, and Telik, aclinical stage oncology drug development company, have entered into a definitive merger agreement.
Drug Research > Drug Discovery & Development > News
Nymox announces completion of second Phase III NX-1207 trial for BPH
Nymox Pharmaceutical has announced that the last enrolled patient has completed participation in the company's pivotal Phase III clinical trial, NX02-0018.
Drug Research > Drug Discovery & Development > News
Janssen announces expanded collaboration with International Partnership for Microbicides
Janssen R&D Ireland (Janssen) has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV.
Drug Research > Drug Discovery & Development > News
Debiopharm, Yale to develop MIF inhibitors to treat autoimmune, inflammatory diseases
By PBR Staff Writer
Swiss biopharmaceutical firm Debiopharm Group has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, to discover MIF inhibitors for the treatment of autoimmune and inflammatory diseases.
Drug Research > Drug Discovery & Development > News
Evotec, Eternygen to discover and develop new metabolic disease therapy
By PBR Staff Writer
German pharmaceutical firms Evotec and Eternygen have entered into a drug discovery collaboration to develop new small molecule inhibitors.
Drug Research > Drug Discovery & Development > News
Regeneron, Avalanche to develop new gene therapy products in ophthalmology
By PBR Staff Writer
Regeneron Pharmaceuticals and Avalanche Biotechnologies have formed a broad collaboration to discover, develop and commercialize new gene therapy products for the treatment of ophthalmologic diseases.
Drug Research > Drug Discovery & Development > News
Auven Therapeutics, Bellus Health announce license agreement with Mount Sinai for Kiacta in sarcoidosis
Auven Therapeutics and Bellus Health have announced that Auven has entered into a license agreement with the Icahn School of Medicine at Mount Sinai in New York, under which the company obtains rights to develop Kiacta (eprodisate) as a treatment for chronic sarcoidosis.
Drug Research > Drug Discovery & Development > News
DSMB recommends stopping Vintafolide PROCEED Phase III trial
Merck and Endocyte have announced that the Data Safety Monitoring Board (DSMB) of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped because vintafolide did not demonstrate efficacy on the pre-specified outcome of progression-free survival (PFS) in patients with platinum-resistant ovarian cancer.
Drug Research > Drug Discovery & Development > News
FDA issues complete response letter for Plumiaz
Acorda Therapeutics has announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for Plumiaz (diazepam) nasal spray for the treatment of people with epilepsy who experience cluster seizures.
Drug Research > Drug Discovery & Development > News
Ruthigen submits IND application to FDA for Phase I/II clinical trial of RUT58-60
By PBR Staff Writer
Ruthigen has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for clinical trial of RUT58-60, a new chemical formulation containing hypochlorous acid (HOCl) with no hypochlorite that utilizes other small molecule stabilizers such as magnesium.
Drug Research > Drug Discovery & Development > News
ANI Pharma, Sofgen Pharma sign agreement to develop ANDA soft gel oral drug product
By PBR Staff Writer
ANI Pharmaceuticals, an integrated specialty pharmaceutical company, and Sofgen Pharmaceuticals, a niche pharmaceutical company, have signed an exclusive licensing, development and supply agreement for the development of an ANDA soft gel oral drug product.
Drug Research > Drug Discovery & Development > News
Merrimack Pharma announces MM-398 achieves primary endpoint in Phase III study
Merrimack Pharmaceuticals has announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone.
Drug Research > Drug Discovery & Development > News
Nova Laboratories receives FDA approval for acute lymphoblastic leukemia drug
By PBR Staff Writer
UK-based Nova Laboratories has received approval from the US Food and Drug Administration (FDA) for its acute lymphoblastic leukemia (ALL) drug Xaluprine, which will be marketed as Purixan in the US.
Drug Research > Drug Discovery & Development > News
61-75 of 3716 results